Amgen Inc. (AMGN)

201.94
3.10 1.50
NASDAQ : Health Technology
Prev Close 198.89
Open 198.38
Day Low/High 197.98 / 202.53
52 Wk Low/High 163.31 / 210.19
Volume 2.32M
Avg Volume 2.94M
Exchange NASDAQ
Shares Outstanding 637.22M
Market Cap 127.05B
EPS 2.70
P/E Ratio 51.92
Div & Yield 5.80 (2.68%)

Latest News

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

Weekly Roundup

The Dow, S&P 500 and Nasdaq all finished higher this week.

Keep These Themes In Mind

They continue to work in this market and we believe can drive growth longer-term.

Healthcare Updates

We have received a number of updates from analysts on the JP Morgan healthcare conference.

EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

EVENITY™ (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture

EVENITY Approved to Reduce the Risk of Fractures and Increase Bone Mineral Density in Men and Postmenopausal Women With Osteoporosis at High Risk of Fracture

Amgen Is a Bright Spot in This Stock Market: Here's How to Play It

Amgen Is a Bright Spot in This Stock Market: Here's How to Play It

After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.

Markets Open Higher on Tuesday as Trade Talks Make Progress

Plus, oil is up and portfolio name Danaher makes a positive pre-announcement.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

The Repatha Pre-Filled Syringe and Repatha Pushtronex® System are Now Available at a Reduced List Price of $5,850

Weekly Roundup

Markets kicked off 2019 with more days of volatility.

Sifting for Stocks That Held Up in Today's Market Carnage

It was a rough day for U.S. equity markets as the Dow plunged 660 points.

Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference

Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan.

Video: Jim's Daily Rundown for Thursday

Jim discusses Thursday's market selloff, what Apple's preannouncement means for the stock long term, the announced Bristol-Myers Squibb acquisition of Celgene and how it relates to Amgen, the oil market, and much more!

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Analyzing Market Themes This New Year's Eve

We believe the potential of a trade deal has increased in recent weeks so we are hesitant to sell into its strength.

AbbVie: The Perfect Stock for High Yield and Growth

ABBV offers an ideal mix of growth, value and income.

Weekly Roundup

Markets remain treacherous as investors are becoming increasingly concerned about a number of factors.

We Don't Care Where Stocks Have Been, We Care Where They Are Going Next

If we see downside being priced in, that creates the opporunity to buy.

Video: Jim's Daily Rundown for Thursday

Jim discusses the Fed decision to raise interest rates and its impact on the markets, what stocks/sectors he is interested in for 2019, and a number of Portfolio names.

Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)

Amgen Submits Supplemental Biologics License Application For Nplate® (romiplostim)

Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules

Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners

Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners

Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology

S&P 500 Q3 2018 Buybacks Surpass $200 Billion Mark For The First Time Ever

S&P 500 Q3 2018 Buybacks Surpass $200 Billion Mark For The First Time Ever

- Q3 share repurchases increase 57.7% year over year to a record $203.8 billion

Amgen Submits Biologics License Application For ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Amgen Submits Biologics License Application For ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration

Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis

TheStreet Quant Rating: B- (Buy)